Camrelizumab

DB14776InvestigationalProtein Based Therapies

Camrelizumab is under investigation in clinical trial NCT03417895 (SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard Therapy).

Mechanism: Pharmacologically active on Programmed cell death protein 1
Curator reviewed
Also known as: Carillizumab · Carrelizumab
Code names: SHR-1210

Resolves to

Compound

UNII73096E137ECAS1798286-48-2

Targets

Q15116PDCD1

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

382Drug interactionsStructured to mechanism, not free text

508Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Camrelizumab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account